<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Potassium acetate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Potassium acetate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Potassium acetate: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12216" href="/d/html/12216.html" rel="external">see "Potassium acetate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13033" href="/d/html/13033.html" rel="external">see "Potassium acetate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F211546"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Electrolyte Supplement, Parenteral</li></ul></div>
<div class="block doa drugH1Div" id="F211535"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> All doses in this monograph are expressed as mEq of potassium (1 mEq = 1 mmol potassium). <b>Safety: </b>Do <b>NOT</b> administer undiluted or by IV push; may cause fatal cardiac arrest. To prevent adverse effects, adhere to standard dilution(s) and rate(s) of administration while closely monitoring serum potassium levels; cardiac monitoring may be required depending on clinical status and infusion rate (eg, &gt;10 mEq/hour [consider all IV potassium sources]); refer to institutional protocols (Kraft 2005).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="04b25be2-c11a-453b-bd96-7677d7805c9b">Hypokalemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia, treatment:</b>
<b>Note:</b> Typically, potassium <i>chloride</i> is preferred because it corrects serum concentrations more quickly than other salts and hypochloremia may develop with potassium acetate use (Asmar 2012; Cohn 2000). Consider use in patients with hypokalemia accompanied by metabolic acidosis (eg, due to diarrhea or renal tubular acidosis) (Kraft 2005). Individualize dosing based on serum potassium levels and clinical factors (eg, underlying cause, presence of symptoms, concomitant medications, ongoing potassium losses) (Clase 2020). Use caution in patients with redistributive hypokalemia (eg, hypokalemic periodic paralysis, theophylline poisoning), as small amounts of administered potassium may result in rebound hyperkalemia and associated cardiotoxicity (Gutmann 2022; Perry 2022). Concurrent hypomagnesemia requires correction to facilitate potassium repletion (Kraft 2005). General guidance is provided below; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Mild to moderate (serum potassium 3 to 3.4 mEq/L):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> IV route is generally used when patient is unable to tolerate oral therapy. Central-line infusion and continuous ECG monitoring highly recommended for infusions &gt;10 mEq/hour (Kraft 2005).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 20 to 60 mEq once based on serum potassium concentration and clinical factors; maximum infusion rate 10 to 20 mEq/<b>hour</b>; base subsequent dosing on serum potassium monitoring (Kraft 2005; Todd 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Severe (serum potassium &lt;3 mEq/L) or symptomatic:</i></b>
<b> Note: </b>Frequent serum potassium monitoring (eg, every 2 to 4 hours) is recommended to determine subsequent dosing (Kraft 2005; Mount 2022). Central-line infusion and continuous ECG monitoring highly recommended for infusion &gt;10 mEq/hour (Kraft 2005).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Serum potassium 2.5 to 3 mEq/L:</i></b>
<b>IV:</b> Initial: 10 to 20 mEq/<b>hour</b>; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hour with continuous ECG monitoring (Couture 2013; Flurie 2017; Hijazi 2005).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Serum potassium &lt;2.5 mEq/L or life-threatening hypokalemia (<span style="text-decoration: underline">not</span> for emergency treatment of cardiac arrest):</i></b>
<b>IV:</b> Initial: 10 to 40 mEq/<b>hour</b>; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hour with continuous ECG monitoring; some patients may require up to 400 mEq per 24 hours (Couture 2013; Flurie 2017; MacLaren 1999).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990472"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Reduce initial dose by at least 50% in patients with renal impairment (Kraft 2005). Potassium acetate administration may also increase serum aluminum and bicarbonate. Contraindicated in patients with renal failure.</p></div>
<div class="block doha drugH1Div" id="F50987732"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in the manufacturer's labeling. Use with caution due to impaired liver utilization of bicarbonate.</p></div>
<div class="block doe drugH1Div" id="F211536"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F211541"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13033" href="/d/html/13033.html" rel="external">see "Potassium acetate: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>
<b>Do NOT administer undiluted or by IV push; may cause fatal cardiac arrest.</b> To prevent adverse effects, adhere to standard dilution(s) and rate(s) of administration while closely monitoring serum potassium levels; cardiac monitoring may be required depending on clinical status and infusion rate.</p>
<p style="text-indent:-2em;margin-left:2em;">Maintenance potassium IV doses should be incorporated into the patient's maintenance IV fluids; intermittent IV potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent IV doses &gt;0.5 mEq/kg/<b>hour</b>. Acid/base balance should be considered when selecting a potassium salt for maintenance therapy or treatment of hypokalemia; acetate is converted to bicarbonate in the body and may affect serum pH. Doses listed as mEq of <b>potassium</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1988e139-ea95-41b9-be4b-84cb139db89b">Hypokalemia, treatment; severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia, treatment; severe: </b>Infants, Children, and Adolescents: Intermittent IV infusion: 0.5 to 1 mEq/kg/dose; maximum dose: 40 mEq/dose; continuous ECG monitoring should be used for intermittent IV doses &gt;0.5 mEq/kg/<b>hour </b>(see "Administration: Pediatric" for more detail on rate) (ASPEN [Corkins 2015]; Greenbaum 2020; Lynch 2017); serum concentrations should be evaluated 1 to 2 hours after completion of infusion; may repeat as needed based on lab values.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97b7bc9f-03a7-4e44-a28d-d32736384506">Parenteral nutrition, maintenance potassium requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance potassium requirement</b> (ASPEN 2020; ASPEN [Corkins 2015]; ASPEN [Mirtallo 2004]):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children weighing ≤50 kg: IV: 2 to 4 mEq/kg/day of potassium as an additive to parenteral nutrition solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Children weighing &gt;50 kg and Adolescents: IV: 1 to 2 mEq/kg/day of potassium as an additive to parenteral nutrition solution.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51154199"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: IV: There are no specific dosage adjustments provided in the manufacturer's labeling. Based on experience in adult patients, reduce initial dose by at least 50% in patients with renal impairment (Kraft 2005). Potassium acetate administration may also increase serum aluminum and bicarbonate serum concentrations. Contraindicated in patients with renal failure.</p></div>
<div class="block dohp drugH1Div" id="F51154200"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution due to impaired liver utilization of bicarbonate.</p></div>
<div class="block adr drugH1Div" id="F211517"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrhythmia, heart block, hypotension, paralysis, paresthesia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Abnormal electroencephalogram, confusion, lethargy</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Local tissue necrosis (with extravasation)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Weakness</p></div>
<div class="block coi drugH1Div" id="F211528"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe renal impairment or adrenal insufficiency; hyperkalemia</p></div>
<div class="block war drugH1Div" id="F211514"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant/irritant (at concentrations &gt;0.1 mEq/mL); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely. In patients with metabolic or respiratory alkalosis, use with caution since use of potassium acetate may worsen alkalosis depending on the amount administered (Khanna 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (eg, untreated Addison's disease, heat cramps, severe tissue breakdown from trauma or burns).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Contraindicated with severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEIs, potassium-sparing diuretics, potassium containing salt substitutes).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral administration: Use extreme caution with parenteral administration and monitor serum potassium concentrations closely. Evaluate renal function, cardiac and fluid status, and any factors contributing to altered potassium concentrations (eg, acidosis, alkalosis) prior to therapy. Do <b>NOT</b> administer undiluted or IV push; inappropriate parenteral administration may be fatal. Always administer potassium further diluted; refer to appropriate dilution and administration rate recommendations. Pain and phlebitis may occur during parenteral infusion requiring a decrease in infusion rate or potassium concentration.</p></div>
<div class="block foc drugH1Div" id="F211523"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mEq/mL (20 mL, 50 mL, 100 mL)</p></div>
<div class="block geq drugH1Div" id="F211510"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323710"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Potassium Acetate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mEq/mL (per mL): $0.20 - $0.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867980"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mEq/mL (50 mL)</p></div>
<div class="block adm drugH1Div" id="F211525"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Potassium must be diluted prior to parenteral administration. For IV infusion; do <b>not</b> administer IV push. In general, the rate of administration may be dependent on patient condition and specific institution policy. Some clinicians recommend that the maximum concentration for peripheral infusion is 10 mEq/100 mL and maximum rate of administration for peripheral infusion is 10 mEq/hour (Kraft 2005). ECG monitoring is recommended for peripheral or central infusions &gt;10 mEq/hour (Kraft 2005). With central line administration, higher concentrations and more rapid rates of infusion may be used; concentrations of 20 to 40 mEq/100 mL at a maximum rate of 40 mEq/hour via central line have been safely administered (Hamill 1991; Kruse 1990).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant/irritant (at concentrations &gt;0.1 mEq/mL); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (Ong 2020; Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (MacCara 1983; Stefanos 2023; Zenk 1981).</p></div>
<div class="block admp drugH1Div" id="F52613623"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Potassium must be diluted prior to parenteral administration. Do not administer IV push. In general, the dose, concentration of infusion, and rate of administration may be dependent on patient condition and specific institution policy.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion rates (including all sources) (AAP [Shenoi 2020]; Greenbaum 2020; Hamill 1991; Klaus 1989; Kruse 1990; Lafraniere 2006; Lynch 2017; Schaber 1985):</p>
<p style="text-indent:-2em;margin-left:4em;">Noncritical care settings: Usual range: 0.2 to 0.5 mEq/kg/<b>hour</b>; in adults, up to 10 to 20 mEq/<b>hour</b> have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">Critical care settings/situations: General recommendation to infuse at a rate ≤0.5 mEq/kg/<b>hour</b>; higher rates may be used; maximum reported rate: 1 to 2 mEq/kg/<b>hour</b> up to 40 mEq/<b>hour</b>; continuous cardiac monitoring recommended in cases of severe hypokalemia and for rates &gt;0.5 mEq/kg/<b>hour</b>; see institutional policy.</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant/irritant (at concentrations &gt;0.1 mEq/mL); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.</p></div>
<div class="block use drugH1Div" id="F211524"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypokalemia:</b> Treatment and prevention of hypokalemia when it is necessary to avoid chloride or acid/base status requires an additional source of bicarbonate.</p></div>
<div class="block mst drugH1Div" id="F211553"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Potassium acetate may be confused with sodium acetate</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Consider special storage requirements for intravenous potassium salts; IV potassium salts have been administered IVP in error, leading to fatal outcomes.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299911"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F211519"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AMILoride: Potassium Salts may enhance the hyperkalemic effect of AMILoride.  Management: Amiloride and potassium supplements should not be used except in severe or refractory cases of hypokalemia. If coadministered, monitor serum potassium closely as rapid increases in potassium are possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Potassium supplements may be needed to treat/prevent hypokalemia in select patients with heart failure receiving eplerenone and high dose loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium Salts may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Potassium Salts may enhance the hyperkalemic effect of Spironolactone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamterene: Potassium Salts may enhance the hyperkalemic effect of Triamterene. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F13889738"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, pre-eclampsia; may be more likely to develop hyperkalemia) (IOM 2004).</p></div>
<div class="block brc drugH1Div" id="F13889739"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Potassium is excreted into breast milk (IOM 2004).</p></div>
<div class="block dic drugH1Div" id="F54754356"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary reference intakes for elemental potassium:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adults ≥19 years of age: 4.7 g/day (adequate intake value) (IOM 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnant women: 4.7 g/day (adequate intake value) (IOM 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Breastfeeding women: 5.1 g/day (adequate intake value) (IOM 2004).</p></div>
<div class="block mop drugH1Div" id="F13203058"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Electrolytes (including serum potassium, bicarbonate, and magnesium), acid/base status; cardiac monitor (if intermittent infusion or potassium infusion rates 0.5 mEq/kg/hour in children or &gt;10 mEq/hour in adults); to assess adequate replacement, repeat serum potassium level 2 to 4 hours after dose. Monitor IV infusion site for extravasation.</p></div>
<div class="block rer drugH1Div" id="F13203059"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Reference ranges may vary depending on the laboratory</p>
<p style="text-indent:-2em;margin-left:2em;">Serum potassium: 3.5 to 5.2 mEq/L</p></div>
<div class="block pha drugH1Div" id="F211513"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion</p></div>
<div class="block phk drugH1Div" id="F211527"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Enters cells via active transport from extracellular fluid </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58196195"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Addex-kalium</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Potassio acetato | Potassio acetato monico</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26044506">
<a name="26044506"></a>Adeli K, Higgins V, Nieuwesteeg M, et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. <i>Clin Chem</i>. 2015;61(8):1049-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/26044506/pubmed" id="26044506" target="_blank">26044506</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference">
                  American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. http://www.nutritioncare.org/PNDosing. Updated November 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22901631">
<a name="22901631"></a>Asmar A, Mohandas R, Wingo CS. A physiologic-based approach to the treatment of a patient with hypokalemia. <i>Am J Kidney Dis</i>. 2012;60(3):492-497. doi:10.1053/j.ajkd.2012.01.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/22901631/pubmed" id="22901631" target="_blank">22901631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10979053">
<a name="10979053"></a>Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. <i>Arch Intern Med</i>. 2000;160(16):2429-2436. doi:10.1001/archinte.160.16.2429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/10979053/pubmed" id="10979053" target="_blank">10979053</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. 2nd ed. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23616673">
<a name="23616673"></a>Couture J, Létourneau A, Dubuc A, Williamson D. Evaluation of an electrolyte repletion protocol for cardiac surgery intensive care patients. <i>Can J Hosp Pharm</i>. 2013;66(2):96-103. doi:10.4212/cjhp.v66i2.1231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/23616673/pubmed" id="23616673" target="_blank">23616673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flurie.1">
<a name="Flurie.1"></a>Flurie RW, Brophy DF. Disorders of potassium and magnesium homeostasis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. <i>Pharmacotherapy: A Pathophysiologic Approach</i>. 10th ed. McGraw-Hill Education; 2017. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&amp;sectionid=134127639.</div>
</li>
<li>
<div class="reference">
                  Greeley C, Snell J, Colaco A, et al. Pediatric reference ranges for electrolytes and creatinine. <i>Clin Chem</i>. 1993;39(6):1172.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greenbaum.1">
<a name="Greenbaum.1"></a>Greenbaum LA. Electrolyte and acid-base disorders. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap. 68.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gutmann.1">
<a name="Gutmann.1"></a>Gutmann L, Conwit R. Hypokalemic periodic paralysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17667395">
<a name="17667395"></a>Hadaway L. Infiltration and extravasation. <i>Am J Nurs</i>. 2007;107(8):64-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/17667395/pubmed" id="17667395" target="_blank">17667395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2026032">
<a name="2026032"></a>Hamill RJ, Robinson LM, Wexler HR, et al, “Efficacy and Safety of Potassium Infusion Therapy in Hypokalemic Critically Ill Patients,” <i>Crit Care Med</i>, 1991, 19(5):694-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/2026032/pubmed" id="2026032" target="_blank">2026032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15977686">
<a name="15977686"></a>Hijazi M, Al-Ansari M. Protocol-driven vs. physician-driven electrolyte replacement in adult critically ill patients. <i>Ann Saudi Med</i>. 2005;25(2):105-110. doi:10.5144/0256-4947.2005.105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/15977686/pubmed" id="15977686" target="_blank">15977686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine), <i>Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate</i>, Washington, DC: National Academy Press, 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16736446">
<a name="16736446"></a>Khanna A, Kurtzman NA. Metabolic alkalosis. <i>J Nephrol</i>. 2006;19(Suppl 9):S86-S96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/16736446/pubmed" id="16736446" target="_blank">16736446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1737458">
<a name="1737458"></a>Khilnani P, “Electrolyte Abnormalities in Critically Ill Children,” <i>Crit Care Med</i>, 1992, 20(2):241-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/1737458/pubmed" id="1737458" target="_blank">1737458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16085929">
<a name="16085929"></a>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005;62(16):1663-1682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/16085929/pubmed" id="16085929" target="_blank">16085929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2310280">
<a name="2310280"></a>Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. <i>Arch Intern Med</i>. 1990;150(3):613-617.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/2310280/pubmed" id="2310280" target="_blank">2310280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7876399">
<a name="7876399"></a>Kruse JA, Clark VL, Carlson RW, Geheb MA. Concentrated potassium chloride infusions in critically ill patients with hypokalemia. <i>J Clin Pharmacol</i>. 1994;34(11):1077-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/7876399/pubmed" id="7876399" target="_blank">7876399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23115538">
<a name="23115538"></a>Lafreniere JA, Hamilton DP, Carr RR. Assessing the guidelines for potassium replacement in pediatric oncology patients receiving amphotericin B. <i>J Pediatr Pharmacol Ther</i>. 2006;11(4):223-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/23115538/pubmed" id="23115538" target="_blank">23115538</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lo SF. Reference intervals for laboratory tests and procedures. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap. 748.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lynch.1">
<a name="Lynch.1"></a>Lynch R, Wood EG, Neumayr TM. Fluid and electrolyte issues in pediatric critical illness. In: Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017:1007-1025.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maclaren.1">
<a name="Maclaren.1"></a>MacLaren R, Ramsay KB, Liiva MT, Connell KA, Rocker GM, Hall RI. The development and implementation of evidence-based electrolyte replacement guidelines in the intensive care unit. <i>JCPH</i>. 1999;52(6):393-398.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568296">
<a name="15568296"></a>Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/15568296/pubmed" id="15568296" target="_blank">15568296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21297518">
<a name="21297518"></a>Moffett BS, McDade E, Rossano JW, Dickerson HA, Nelson DP. Enteral potassium supplementation in a pediatric cardiac intensive care unit: evaluation of a practice change. <i>Pediatr Crit Care Med</i>. 2011;12(5):552-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/21297518/pubmed" id="21297518" target="_blank">21297518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-mount.1">
<a name="mount.1"></a>Mount DB. Clinical manifestations and treatment of hypokalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference">
                  Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141794">
<a name="33141794"></a>Ong J, Van Gerpen R. Recommendations for management of noncytotoxic vesicant extravasations. <i>J Infus Nurs</i>. 2020;43(6):319-343. doi:10.1097/NAN.0000000000000392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/33141794/pubmed" id="33141794" target="_blank">33141794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-perry.1">
<a name="perry.1"></a>Perry H. Theophylline poisoning. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference">
                  Potassium acetate injection [prescribing information]. Lenoir, NC: Exela Pharma Sciences, LLC.; October 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4011464">
<a name="4011464"></a>Schaber DE, Uden DL, Stone FM, Singh A, Katkov H, Bessinger FB. Intravenous KCl supplementation in pediatric cardiac surgical patients. <i>Pediatr Cardiol</i>. 1985;6(1):25-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/4011464/pubmed" id="4011464" target="_blank">4011464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19969151">
<a name="19969151"></a>Todd SR, Sucher JF, Moore LJ, Turner KL, Hall JB, Moore FA. A multidisciplinary protocol improves electrolyte replacement and its effectiveness. <i>Am J Surg</i>. 2009;198(6):911-915. doi:10.1016/j.amjsurg.2009.04.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-acetate-drug-information/abstract-text/19969151/pubmed" id="19969151" target="_blank">19969151</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9792 Version 177.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
